TRANSGENE
Last · Paris€0.692-0.008 (-1.14%)stale · yahoo · 46h ago
Market cap€192.6M278.3M sh
P/E · TTM-4.1fwd -3.1 · eps -0.17 · loss
Beta0.72vs S&P 500
Div yield0.00%annual · TTM
52w range
€0.679€1.50
Volume45.3Ksession
| Revenue | €1.2M |
|---|---|
| Operating income | €-30.0M |
| Net income | €-22.3M |
| Operating margin | -2537.8% |
| Net margin | -1885.8% |
| Return on equity | -143.0% |
| Period | 2023 |
Loading chart…
OpenFilings analyst
Our analyst
From latest ANNUAL · 2026-04-15
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Runway Low
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -27389.8%
- Cash Runway Low — Cash runway ~0.2 years
- Rd Intensity High — R&D/Revenue 24741.6%
Earnings transcripts
Press & signals
- GlobeNewswire
Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
- GlobeNewswire
Transgene to Participate in Investor Access
- GlobeNewswire
Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags
2026-10-052026-10-050